References |
1 |
Levodopa was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
2 |
DrugBank(Pharmacology-Metabolism)Levodopa
|
3 |
Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
|
4 |
Complexity of dopamine metabolism. Cell Commun Signal. 2013 May 17;11(1):34.
|
5 |
Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
|
6 |
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
|
7 |
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 Jan 18;10(1):310.
|
8 |
Drug metabolism by the host and gut microbiota: a partnership or rivalry? Drug Metab Dispos. 2015 Oct;43(10):1499-504.
|
9 |
Motor complications, levodopa metabolism and progression of Parkinson's disease Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):847-55. doi: 10.1517/17425255.2011.575779.
|
10 |
Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone. J Neural Transm (Vienna). 2021 Jan;128(1):27-36. doi: 10.1007/s00702-020-02267-y.
|
11 |
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Sci Adv. 2021 Jan 6;7(2):eabe5948. doi: 10.1126/sciadv.abe5948. Print 2021 Jan.
|
12 |
Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications. Pharmaceutics. 2021 Sep 3;13(9):1395. doi: 10.3390/pharmaceutics13091395.
|